Use of methylnaltrexone and related compounds
Abstract
A method for preventing or treating opioid induced side effects including dysphoria, pruritus and urinary retention and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered by the route selected from the group consisting of intravenous, intramuscular, transmucosal, transdermal, and oral administration, preferably administered orally in an enterically coated form.
Term
Term ended
Expired 3 November 2018, 7.9 years ago.
- Priority
- Filed
- Granted
- Expired
- Today
28 members in 7 offices
Priority claims9
| Document | Office | Kind | Date |
|---|---|---|---|
| 96274297 | United States of America | A | |
| 12070398 | United States of America | A | |
| 9823485 | United States of America | W | |
| 120703 | – | – | – |
| 962742 | – | – | – |
| PCTUS9823485 | – | – | – |
| US19970962742 | – | – | – |
| US19980120703 | – | – | – |
| WO1998US23485 | – | – | – |
Members28
| Document | Office | Kind | |
|---|---|---|---|
| CA2312234A1 | Canada | A1 | |
| WO9922737A1 | World Intellectual Property Organization (WIPO) | A1 | |
| AU1380299A | Australia | A | |
| US5972954A | United States of America | A | |
| EP1047426A1 | European Patent Office (EPO) | A1 | |
| US6274591B1 | United States of America | B1 | |
| US2002028825A1 | United States of America | A1 | |
| AU758416B2 | Australia | B2 | |
| US2003065003A1 | United States of America | A1 | |
| US6559158B1 | United States of America | B1 | |
| US6608075B2 | United States of America | B2 | |
| US2003158220A1 | United States of America | A1 | |
| US2003187010A1 | United States of America | A1 | |
| EP1047426A4 | European Patent Office (EPO) | A4 | |
| US2004162306A1 | United States of America | A1 | |
| US2004162307A1 | United States of America | A1 | |
| US2004162308A1 | United States of America | A1 | |
| US2004167147A1 | United States of America | A1 | |
| US2004167148A1 | United States of America | A1 | |
| US2005048117A1 | United States of America | A1 | |
| CA2312234C | Canada | C | |
| US2009312359A1 | United States of America | A1 | |
| US2010087472A1 | United States of America | A1 | |
| EP1047426B1 | European Patent Office (EPO) | B1 | |
| ATE467415T1 | Austria | T1 | |
| DE69841663D1This record | Germany | D1 | |
| US2012190702A1 | United States of America | A1 | |
| US2012277260A1 | United States of America | A1 |
1 legal event, as the office reported them to INPADOC
Events
| Event | Code | |
|---|---|---|
| No opposition during term of oppositionOpposition8364 | 8364 |
Numbers
- Publication
- 69841663
- Publication, DOCDB
- 69841663
- Publication, EPODOC
- DE69841663D
- Application
- 69841663
- Application, DOCDB
- 69841663
- Application, EPODOC
- DE19986041663T
Titles2
- German
- VERWENDUNG VON METHYLNALTREXON UND VERWANDTEN VERBINDUNGEN
- English
- USE OF METHYL NALTREXONE AND RELATED COMPOUNDS
Classification
- CPC, 2
- A61K31/485
- A61P1/00
- IPC, 2
- A61K31 485
- A61P1 00